New JAAM Composition

With the aim of having fully independent scientific assessments of the compounds requesting access to the European COVID-19 adaptive platform trials (APTs), the composition of the Joint Access Advisory Mechanism (JAAM) changed in December 2021. Previously composed of the project coordinators, principal investigators and the chairs of the drug prioritization boards of the European COVID-19 APTs, the JAAM is now composed of a panel of seven independent experts with multidisciplinary expertise. This panel is supported by the JAAM Secretariat, and meets on a regular basis to assess proposals from investigators or industry representatives who wish to have their compound tested in the EU APTs. 

Read more about the new JAAM composition and operations here.